| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Artelo Biosciences Inc (NASDAQ: ARTL)
ARTL Technical Analysis
1
| As on 27th Mar 2026 ARTL SHARE Price closed @ 10.54 and we RECOMMEND N/A for LONG-TERM with Stoploss of 0.00 & N/A for SHORT-TERM with Stoploss of 0.00 we also expect STOCK to react on Following IMPORTANT LEVELS. |
ARTLSHARE Price
| Open | 7.99 | Change | Price | % |
| High | 19.91 | 1 Day | N/A | N/A |
| Low | 7.45 | 1 Week | 0.00 | 0.00 |
| Close | 10.54 | 1 Month | 0.00 | 0.00 |
| Volume | 82148461 | 1 Year | 0.00 | 0.00 |
| 52 Week High 0.00 | 52 Week Low 0.00 | ||||
NASDAQ USA Most Active Stocks
| LPTX | 2.05 | 365.91% |
| AMRS | 0.14 | 100.00% |
| WBA | 11.98 | 0.50% |
| NVDA | 167.52 | % |
| LMDX | 0.02 | 0.00% |
| YGMZ | 0.02 | -66.67% |
| TIRX | 0.03 | % |
| ARTL | 10.54 | % |
| LILM | 0.05 | 0.00% |
| PONO | 1.72 | 2.38% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| ARTL Daily Charts |
ARTL Intraday Charts |
Whats New @ Bazaartrend |
ARTL Free Analysis |
|
|
ARTL Important Levels Intraday
| SUPPORT | 0.00 |
| SUPPORT | 0.00 |
| SUPPORT | 0.00 |
| SUPPORT | 0.00 |
| SUPPORT | 0.00 |
| SUPPORT | 0.00 |
| SUPPORT | 0.00 |
| SUPPORT | 0.00 |
ARTL Forecast March 2026
| 4th UP Forecast | 0 |
| 3rd UP Forecast | 0 |
| 2nd UP Forecast | 0 |
| 1st UP Forecast | 0 |
| 1st DOWN Forecast | 0 |
| 2nd DOWN Forecast | 0 |
| 3rd DOWN Forecast | 0 |
| 4th DOWN Forecast | 0 |
ARTL Weekly Forecast
| 4th UP Forecast | 0.00 |
| 3rd UP Forecast | 0.00 |
| 2nd UP Forecast | 0.00 |
| 1st UP Forecast | 0.00 |
| 1st DOWN Forecast | 0.00 |
| 2nd DOWN Forecast | 0.00 |
| 3rd DOWN Forecast | 0.00 |
| 4th DOWN Forecast | 0.00 |
ARTL Forecast2026
| 4th UP Forecast | 0 |
| 3rd UP Forecast | 0 |
| 2nd UP Forecast | 0 |
| 1st UP Forecast | 0 |
| 1st DOWN Forecast | 0 |
| 2nd DOWN Forecast | 0 |
| 3rd DOWN Forecast | 0 |
| 4th DOWN Forecast | 0 |
Artelo Biosciences Inc ( NASDAQ USA Symbol : ARTL )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
ARTL Business Profile
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic G protein-coupled receptor agonist, which is in Phase 1 clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment of inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor for prostate and breast cancer treatment, as well as for treating PTSD. Artelo Biosciences has research collaboration with Trinity College Dublin to Investigate ART27.13 for the treatment of cancer cachexia. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was founded in 2011 and is headquartered in La Jolla, California. Address: 888 Prospect Street, La Jolla, CA, United States, 92037
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service